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tion.
Although not detectably expressed by vascular cells in the human and animal tumors we have studied, VPF/VEGF aarumulates in the microvessels supplying tumors and certain idlammatory reactions in which VPFlVEGF is also overexpressed. Light microscopic immunohistochemistry lacked the resolution necessary to localize VPF/VEGF precisely in such vessels. Therefore, we used a pre-embedding immunocytochemical method to localize VPFlVEGF at the ultrastructural level in the new blood vessels that are elicited in the peritoneal walls of mice bearing a transplantable mouse ascites tumor of ovarian origin. Intense immunostaining for VPFNEGF was observed on the abluminal plasma membrane of tumor-associated microvascular endothelial cells and in vesiculovacuolar organelles (WOs) present in these same endothelial cells. (WOs are recently described cytoplasmic organelles present in tumor vascular endothelium that provide an important pathway for extravasation of circulating maaomolecules.) In contrast to labeling of the abluminal plasma membrane and W O vesicles and vacuoles, endothelial cytoplasmic organelles, such as multivesicular bodies and Weibel-Palade bodies, and the underlying basal lamina, did not stain with antibodies to VPFlVEGF. The distribution of VPFIVEGF here described corresponds to that anticipated for high-affinity VFPlVEGF receptors, although binding of VPFlVEGF to other endothelial cell surface smc-
Introduction
Vascular permeability factor (VPF), also known as vascular endothelial growth factor (VEGF), is synthesized and secreted by a large number of transplantable animal and autochthonous human tumors and by an increasing number of other epithelial and mesenchymal cells, both in vivo and in culture (1-11). VPFIVEGF is one of the most potent known inducers of microvascular (venule and small vein) hyperpermeability (1-3,ll-13). It acts selectively on en-' Supported by USPHS NIH grants AI-33372 and CA-50453.
Correspondence ta AM M. Dvorak dothelial cells by way of receptor tyrosine kinases (flt-1 and KDR) (9, 1448) to increase intracellular calcium (19) and by this mechanism is thought to give the tumor microvasculature one of its characteristic properties, hyperpermeability to circulating macromolecules (2, 20) . VPFlVEGF also induces angiogenesis, probably by both direct and indirect mechanisms (11,21-24). i.e., (a) as an endothelial cell mitogen and (b) by enhancing microvascular hyperpermeability and thereby inducing a provisional, fibrin-rich extracellular matrix that favors endothelial cell migration.
Immunohistochemistry has been useful for demonstrating and localizing VPFIVEGF in human and animal tumors (25-29). Not unexpectedly, antibodies of proven specificity against VPF/VEGF commonly stained the cytoplasm of tumor cells that expressed VPFIVEGF "A.
Of greater interest, however, is that certain of these antibodies also intensely and selectively stained tumorassociated microvessels, structures that do not express VPFlVEGF mRNA (25-29). Presumably, therefore, this staining reflected VPFlVEGF that had been secreted by nearby tumor cells and that had become bound to microvessels. In fact, this view is consistent with the concept that tumor cell-secreted VPNVEGF acts in paracrine fashion on nearby microvascular endothelial cell targets to increase both vascular permeability and endothelial cell division. Light microscopic immunohistochemistry lacked the resolution necessary to localize VPFlVEGF precisely within tumor-associated microvessels. Such information is important for localizing endothelial cell binding sites for VPFlVEGF and ultimately for elucidating the mechanisms by which VPF/VEGF exerts its effects on microvascular endothelium. To this end, we extended our immunohistochemical methodology to the ultrastructural level, choosing for study a mouse ovarian tumor (MOT) known to express VPFlVEGF and whose associated microvessels stained strongly with antibodies to VPFlVEGF when grown in either solid or ascites form (30-33). We here report localization of VPF/VEGF primarily to the abluminal plasma membrane of tumor-associated microvascular endothelium and also to vesiculovacuolar organelles (WOs), recently described endothelial cell cytoplasmic structures that are involved in transendothelial cell transport of circulating macromolecules (34).
Materials and Methods
Animals and Tumor. Mouse ovarian tumor (MOT) was passaged in ascites form in syngeneic C3HeblFeJ mice (32). This tumor induces a strong angiogenic response within peritoneal lining tissues, permitting study of large numbers of tumor-induced blood vessels without interference from admixed tumor cells that remain suspended in peritoneal ascites fluid or that adhere to but usually do not invade the peritoneal wall (30-32).
For the studies reported here. six adult male C3HeblFeJ mice (4-6 weeks old, 15-20 g BW) were injected with 1.0 x lo6 MOT cells. Thirteen days later. when angiogenesis in the peritoneal lining was near maximal. mice were sacrificed with dry ice and ether and the parietal peritoneum and attached muscle were rapidly removed and fixed in 3.7% paraformaldehyde-O.5% glutaraldehydc-0.2% 2-mercaptoethanol in 0.1 M PBS, pH 7.6. for 60 min at room temperature (RT).
Tissue Preparation. After two washes in 0.1 M PBS. pH 7.6, tissues were stored overnight at 4'C in 0.05 M PBS. p H 7.6. containing 7% sucrose. Tissues were then immersed in 0.05 M PBS supplemented first with 15% sucrose for 4 h at 4'C and then with 25% sucrose and 10% glycerol for 2 h at 4°C. Finally, tissues were embedded in OCT compound (Miles; Elkhart, IN) and snap-frozen in a mixture of dry ice and acetone. Frozen scctions. 4 or 12 pm thick, were cut on a standard cryostat (Tissue-Tek 11) and were collected on 3-aminopropyltriethoxy-silane (Sigma; St Louis, MO)coated glass slides. Slides were transferred immediately to 0.1 M PBS. pH 7.6, taking care that the tissue sections did not dry out.
Immunoperoxidase Protocol. Four-pm sections were used for light microscopic immunohistochemistry and 12-pm sections were processed according to the same protocol for subsequent embedment in Epon for I-pm light microscopic sections and for electron microscopic immunocytochcmistry. After immunohistochemistry, 4,pm sections wcrc counterstained with modified Mapr's hematoxylin (American Histology Reagent; Stockton. CA).
All of the following immunostaining steps except for step h were performed at RT with the cryostat-cut sections mounted on glass slides: (a) 0.1% sodium borohydride (Sigma) in 0.1 M Tris-buffered saline (TBS) (Sigma). pH 7.4, 30 min; (b) three washes in 0.1 M PBS. pH 7.6. 10 min each; (c) 0.05% Triton X-100 (Sigma) in 0.1 M PBS. pH 7.6, 10 min; (d) two washes in 0.1 M PBS. pH 7.6. with 0.2% bovine serum albumin (BSA; Sigma). 10 min each; (e) 0.6% HzOz (Fisher Scientific; Fair Lawn. NJ) in methanol. 10 min; (f) two washes in 0.1 M PBS. pH 7.6, with 0.2% BSA. 10 min each; (g) 5% normal goat serum (NGS) (Life Technologies; Grand Island, NY) in 0.1 M PBS. pH 7.6, for 60 min; (h) primary antibody, an affinity-purified rabbit antibody prepared against a synthetic peptide representing the 25 amino acids of the N-terminus of rat VPFNEGF. This antibody reacts specifically with both mouse and rat VPFlVEGF by Western blotting (Figure 1 ) (30. 35 ). The flow-through from the affinity column antibody purification was also tested and showed no positive staining (not shown). The affinity-purified anti-VPFN-terminusantibody has been particularly useful for immunohistochemical localization of VPFlVEGF in appropriately prepared tissue sections (28JO. [36] [37] [38] . The primary antibody was used at a dilution of 1:300 (= 1.8 kg proteinlml) in 0.1 M PBS with 1% NGS. overnight at 4'C (i) three washes in 0.1 M PBS, pH 7.6, with 2% NGS.. Controls for Immunostaining. Six separate controls were performed to ensure the specificity of immunostaining: (a) primary antibody was absorbed on an affinity column in which the specific NHz-terminal VPF/VEGF peptide was coupled to CNBr-activated Sepharose 4B (Pharmacia; Piscataway, NJ); (b) an irrelevant rabbit IgG antibody [prepared against human osteopontin (39) ] was substituted for the specific primary antibody at equivalent protein concentration: (c) omission of specific primary antibody: (d) omission of the secondary antibody: (e) omission of the ABC complex: (f) omission of DAB.
One-pm Epon Sections and Electron Microscopy. After immunostaining, 12-km sections attached to glass slides were postfixed in 1.33% os04 in 0.2 M Sym-collidine buffer, pH 7.4, for 120 min at 4'C, dehydrated in a graded series of alcohols, and infiltrated with a propylene oxide-Epon 812 sequence. Embedment was performed by inverting Epon-filled BEEM capsules over the slide-attached tissue sections. After polymerization for 16 hat 60"C, Epon blocks w: r e separated from glass slides by briefimmersion in liquid nitrogen.
One-pm plastic sections were counterstained with either 0.5% toluidine blue in 0.5% sodium borate, pH 7.85, or Giemsa stain, pH 6.95, and were examined by light microscopy. For electron microscopy, thin sections were cut with an LKB IV ultratome (LKB Bromma, Sweden), placed on uncoated, 200-mesh copper grids (Ted Pella; Austin, CA), and either stained with lead citrate for 2 min or left unstained. Grids were viewed in a Philips 300 transmission electron microscope (Philips North America; Mahwah, NJ).
Western Blotting. Western blots were perfouned on tumor ascites fluid with the Proto Blot AP system (Promega; Madison, WI) using affinitypurified polyclonal antibody against the NH2-terminal peptide of rat VPF, previously shown to crossreact with mouse VPF (30). Ascites fluid from a 14-day MOT ascites tumor-bearing mouse was centrifuged at 1000 g for 10 min to pellet the tumor cells. The cell-free axites fluid was diluted 1:20 in sample buffer containing dithiothreitol, analyzed by SDS-PAGE on a 4-20% precast gradient gel (Novex; San Diego, CA) under reducing conditions, and transferred to nitrocellulose membrane (Novex). The membrane was blocked in Blotto (5% non-fat dry milk, 2 mM CaC12, 0.05% Tween-20,0.01% Antifoam A, 50 mM Tris, pH 8.0) for 1 h at RT and subsequently incubated at 4°C overnight with either affinity-purified anti-rat VPF polyclonal antibody or normal rabbit IgG (at an equivalent protein concentration) diluted in Blotto. The membrane was washed three times with Blotto for 20 min and incubated with anti-rabbit IgG-AP conjugate for 1 h at RT After washing with Blotto. TBST (150 m M NaCI, 10 mM %is-HC1, pH8.0,0.05% Tween-lo), TBS(150mMNaCI,10mMTris-HC1, pH 8.0), and AP buffer (100 mM NaCI, 5 mM MgC12, 100 mM Tris-HCI, pH 9.5) for 10 min each, the membrane was incubated with substrate sohtion containing 66 ~l NBT (nitroblue tetrazolium; Promega), 33 PI BCIP (bromo-4-chloro-3-indolyl phosphate; Promega). and 10 ml AP buffer.
scopic results and allowed definitive localization of VPF/VEGF reaction product (Figures 3-5). At low magnifications the abluminal endothelial cell plasma membrane was stained densely and often uniformly, but the underlying basal lamina did not stain ( Figures  2 and 3) . In contrast to the abluminal plasma membrane, the luminal plasma membrane of endothelial cells was usually negative ( Figures 5C and 5F) , as were the lateral plasma membranes that
Results

Immunohistochemical Localization of WF/VEGF in Peritoneal Lining Microvessels
MOT ascites tumors induced a strong angiogenic response in the peritoneal wall and other peritoneal lining tissues (30-32,38). The angiogenic response peaked at about 2 weeks after IP injection of tumor cells (32) and at that time was composed of large numbers of thin-walled vessels confined to a narrow band within approximately 100 pm of the peritoneal surface (Figure 2A) .
Newly induced blood vessels exhibited strikingly intense and highly specific staining for VPF/VEGF (Figures 2A and 2C-2E) , whereas an irrelevant primary antibody was consistently negative ( Figure 2B ). Vessels closest to the peritoneal surface stained most intensely with specific anti-VPFIVEGF antibodies and those at a distance of more than m300 pm from the peritoneal surface did not stain at all. Vessel staining was circumferential and seemed to involve primarily abluminal portions of lining endothelial cells ( Figures 2C-2E ). However, focal positive punctate foci were also identified within endothelial cell cytoplasm; nuclear staining was not observed. Endothelial cell mitoses were not uncommon (Figure 2D ). Nagy et al. (32) have described bridging of endothelial cell cytoplasmic processes across the lumens of new, enlarged peritoneal wall vessels in ascites tumor-bearing animals, and sometimes these "bridges" also exhibited positive staining for VPFIVEGF (Figure 2E ).
Ultrastructure of the Microvessels Newly Induced in the Peritoneal Wall by MOT Ascites E m o r s
These vessels were lined for the most part by a continuous endothelium, but focal areas of fenestrated endothelium were infrequently present, as previously reported (34, 40) . Interendothelial cell junctions did not show gaps (40) . Prominent cytoplasmic organelles included vesiculovacuolar organelles (WOs), mitochondria, cytoskeletal filaments, plasmalemma1 caveolae, Weibel-Palade bodies, coated vesicles, and multivesicular bodies. WOs are grapelike clusters of interconnected, membrane-bounded, caveola-sized vesicles and larger vacuoles that are distributed at intervals in the cytoplasm of endothelial cells in tumor microvessels and in normal venules 
Immunocytochemical LocaZization of WF/VEGF in Peritoneal Lining Microvessels
Ultrastructural immunocytochemistry confirmed the light micro-formed interendothelial cell junctions. Focal patches of luminal plasma membrane were stained for VPFlVEGF ( Figure 4A) .
At higher magnifications, VPF/VEGF staining was also localized to the cytoplasmic vesicles and vacuoles comprising WOs (Figures 3,4A , 4C, and 5A-5C). WOs often span the endothelial cell cytoplasm from blood to tissue fronts and have been identified as the primary pathway by which circulating macromolecules exit leaky tumor blood vessels (34; and Dvorak AM et al., submitted for publication). Individual vesicles and vacuoles that formed cytoplasm portions of WOs and that were situated in abluminal portions of endothelial cell cytoplasm ( Figures 3A. 4C , and SA) stained more frequently and intensely with antibodies to VPF/VEGF than did similar structures located closer to the luminal front ( Fig  ure SC) . Sometimes reaction product was found in vesicles and vacuoles whose cytoplasmic location was close to the luminal surface or even opened to the blood front; rarely, the luminal plasma membrane also exhibited focal staining ( Figure 4A ).
Other endothelial cell structures, such as multivesicular bodies ( Figure >F) , coated vesicles, Weibel-Palade bodies, lysosomes, mitochondria, and nuclei, did not stain for VPF/VEGF. All of the controls described in Materials and Methods were negative, i.e., no positive immunostaining was observed by either light or electron microscopy ( Figures 2B, 3B , 4B, 4D, 5D, and >E). To confirm that the affinity-purified polyclonal antibody against the NHz-terminal peptide of rat VPF was specific for murine VPF, we compared the immunoreactivity of the affinity-purified antibody vs that of normal rabbit immunoglobulin at an equivalent protein concentration, using as antigen the complex mixture of proteins contained in MOT tumor ascites fluid. It has been shown previously that MOT ascites fluid contains VPF (30). Immunoblatting analysis indicated that the affinity-purified anti-VPF antibody specifically recognized only two polypeptides of 24 and 18 KD, identical in size to the polypeptides of the two secreted forms of murine VPF.
Discussion
Electron microscopic immunocytochemistry permitted precise subcellular localization of VPF/VEGF deposition in the new microvessels that formed in the peritoneal lining tissues of MOT ascites tumor-bearing mice. Previously, light microscopic immunohistochemistry identified VPFlVEGF in the microvessels of MOT and other mouse, guinea pig, and human tumors growing in either solid or ascites form (26-30,38) but lacked the resolution necessary to determine whether staining was present in endothelial cell cytoplasm, on endothelial cell surfaces, or in the vascular basal lamina. The ultrastructural data reported here have now localized bound VPF/VEGF primarily to the abluminal plasma membrane of endothelial cells and to the cytoplasmic vesicles and vacuoles that comprise endothelial cell WOs, particularly those situated in ablumi- nal portions of endothelial cell cytoplasm. The vascular basal lamina and lateral endothelial cell plasma membranes were negative for VPFlVEGF, even in strongly stained microvessels. Positive staining was occasionally observed in W O vesicles and vacuoles close to the vascular lumen and sometimes focally on the luminal plasma membrane. However, VPFlVEGF was not found within cytoplasmic structures associated with receptor-mediated endocytosis or proteolytic breakdown, e.g., coated vesicles, multivesicular bodies, and lysosomes.
A number of studies have demonstrated that VPFNEGF is not synthesized at detectable levels by tumor-associated or other blood vessels in vivo (2,3). However, tumor cells growing in suspension in the peritoneal cavity synthesize and secrete relatively large amounts of VPF/VEGF (30J3.41) and provide the most likely source of the VPFlVEGF deposited in peritoneal wall microvessels. At 13 days after IP injection of MOT cells, the concentration of VPFNEGF in ascites fluid exceeds 2.0 nM (30). The most common VPF/VEGF isoform secreted by tumor cells is a highly soluble dimeric peptide of G i 5 KD which would be expected to diffuse into peritoneal tissues. In fact, diffusion of tumor cell-secreted VPFlVEGF from ascites fluid into the peritoneal wall likely explains the several steeply declining gradients we observed in the peritoneal wall with increasing distance from the peritoneal surface. These declining gradients included (a) VPFlVEGF staining intensity of microvessels, (b) frequency of new blood vessels (VPFlVEGF is a mediator of angiogenesis), and (c) VPFlVEGF staining of the peritoneal wall extracellular matrix (30-32).
We do not know at present whether the VPFlVEGF we have visualized by immunocytochemistry in tumor microvascular endothelium is bound to either of the two high-affinity receptor tyrosine kinases thought to transduce VPFlVEGF signalling (9.14-18). Both of these receptors are believed to reside in endothelial cell plasma membranes, but finer characterization of their distribution (e.g., presence in luminal, lateral, andlor abluminal portions of these membranes) awaits the development of appropriate antireceptor antibodies suitable for immunocytochemistry. In the absence offurther information, it is reasonable to anticipate that these receptors are concentrated in the abluminal plasma membranes of vascular endothelium, the first endothelial cell surface that would encounter VPFIVEGF that is secreted into tissues by tumor or other cells. VPFlVEGF receptors might also be represented in WOs, the cytoplasmic clusters of uncoated vesicles and vacuoles that provide the primary pathway by which circulating macromolecules extravasate from leaky tumor microvessels (34; and Dvorak AM, submitted for publication). If, as presently believed, VPFlVEGF is responsible for the hyperpermeability of tumor-associated vessels, it probably exerts this hyperpermeability effect, directly or indirectly, by upregulating W O function. In summary, therefore. the deposits of VPFlVEGF we have observed on the abluminal surface of vascular endothelium and in vesicles and vacuoles of the W O organelle correspond closely to the distribution anticipated ifVPFlVEGF were to increase microvascular permeability by upregulating W O function.
However, endothelial cell-associated VPFlVEGF might also re- flect binding to plasma membrane structures other than transducing receptors. VPF/VEGF binds to heparin (42), and digestion of heparan sulfates from cultured endothelium substantially reduces the binding of VPF/VEGF to cultured endothelial cells (43) . Therefore, the VPF/VEGF we have visualized on tumor endothelium might reflect binding to surface proteoglycans, and, indeed, proteoglycan co-receptors have been described for a number of other cytokines, including basic FGF (44) and transforming growth fac-tor-p (45). Proteoglycan co-receptors may have an important role in presenting cytokines to transducing membrane receptor proteins. VPF/VEGF also exerts maximal biological &em at subpicomolar to low nanomolar concentrations, and, based on Scatchard plots, two VPF/VEGF receptors were predicted, one with a frequency of -2600 per cell, another with a frequency of 34,000 per cell (43) . It seems unlikely that immunocytochemical methods could detect the small numbers of VPFIVEGF molecules that would saturate such rcccpton. On the other hand, it is clear that the mRNAs of both flt-1 and KDR arc strikingly overcxprcsscd in the microvascular cndothclium adjacent to tumors or othcr sitcs of VPFlVEGF overproduction (4.7.26-28.46.47). Thcrcforc, thc numbcn of mcmbranc rcccpton prcscnt in tumor microvascular cndothclium may bc much higher than those that have been estimated on culturcd cndothclial cclls dcrivcd from non-tumor sourccs. If so, thcn it is possible that much of the VPFlVEGF visualized by immunocytochemistry on tumor vascular cndothclium is associated with highaffinity rcccptors such as flt-1 and KDR. Binding of VPWVEGF to endothelial cell surfaces may scrvc other functions in addition to initiation of signal transduction. For ex-ample, binding of VPFlVEGF to nearby cndothclial cells might scrvc to limit its disscmination and thus could prcvcnt this potent cytokinc from diffusing to distant sitcs where its cffccts might prow harmful. In addition, such binding could bc a preludc to ligand endocytosis and proteolysis. although wc did not detect VPFIVEGF in cndothclial cytoplasmic structures normally engaged in such activities. such as cndosomcs, lysosomcs. and multivcsicular bodies.
In summary, wc have localizcd VPFlVEGF to thc abluminal plasma mcmbranes and to W O vcsiclcs and vacuolcs of cndothclial cells immediately adjacent to sitcs of ascites tumor growth. Thc vcsscls that stained with antibodies to VPFlVEGF arc those that cxhibitcd both of the major rcsponscs elicited by VPFlVEGF, i.e.. increased microvascular permeability and endothelial cell division (30-32). It is likely that the endothelial cell-associated VPF/WGF functions to activate signal transduction pathways that regulate both microvascular permeability and endothelial cell growth. Moreover, endothelial cell-associated VPFNEGF seems to provide a selective marker for the microvasculature that supplies many types of animal and human tumors and could therefore have utility in diagnosis or as a target for tumor therapy (28,48). Leimgruber 
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